{"id":385690,"date":"2020-11-19T17:03:20","date_gmt":"2020-11-19T22:03:20","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=385690"},"modified":"2020-11-19T17:03:20","modified_gmt":"2020-11-19T22:03:20","slug":"mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\/","title":{"rendered":"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">WESTLAKE VILLAGE, Calif., Nov.  19, 2020  (GLOBE NEWSWIRE) &#8212; MannKind Corporation\u00a0(NASDAQ:MNKD) today announced that it has achieved the final development milestone under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil.<\/p>\n<p align=\"justify\">Treprostinil Technosphere (\u201cTreT\u201d) is an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension (PAH). All current clinical trials are now fully enrolled, including the BREEZE study in patients with PAH and a pivotal pharmacokinetics study in healthy subjects, both of which are being conducted by United Therapeutics, as well as a human factors study being conducted by MannKind. In addition, MannKind\u2019s stability program for TreT has reached the milestone required for a regulatory filing.<\/p>\n<p align=\"justify\">\u201cWe are looking forward to working with United Therapeutics during the first part of 2021 to prepare an FDA submission for TreT,\u201d said Michael Castagna, Chief Executive Officer of MannKind.<\/p>\n<p align=\"justify\">MannKind has now received all of the milestone payments that were specified in its agreement with United Therapeutics. MannKind remains entitled to receive low double-digit royalties on net sales of TreT. MannKind will also manufacture supplies of TreT for United Therapeutics and will earn a manufacturing margin.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0Mann<\/strong><br \/>\n        <strong>Kind <\/strong><br \/>\n        <strong>Corporation<\/strong><\/p>\n<p>MannKind Corporation\u00a0(NASDAQ: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind\u00a0is currently commercializing Afrezza\u00ae (insulin human) Inhalation Powder, the Company\u2019s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in\u00a0the United States, where it is available by prescription from pharmacies nationwide.\u00a0MannKind\u00a0is headquartered in\u00a0Westlake Village, California, and has a state-of-the art manufacturing facility in\u00a0Danbury, Connecticut. The Company also employs field sales and medical representatives across the\u00a0U.S.\u00a0For further information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EP5JYKcdu9gNRgpkJLrhIN31GLLoUhZ0ZnKnGL2CNm4gaxOF4wN9hnCYF2Z9YQYJC6VP4hlOrytndq4mDSbZrfNkmNimXlpDN5imdECHIPk=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.mannkindcorp.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        \n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements that involve risks and uncertainties. Words such as &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;will,&#8221; &#8220;goal,&#8221; &#8220;potential&#8221; and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon\u00a0MannKind&#8217;s\u00a0current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties detailed in\u00a0MannKind&#8217;s\u00a0filings with the\u00a0SEC. For a discussion of these and other factors, please refer to MannKind\u2019s annual report on Form 10-K for the year ended\u00a0December 31, 2019 as well as MannKind\u2019s other filings with the\u00a0SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and\u00a0MannKind\u00a0undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.<\/p>\n<p>\n        <strong>Company Contact<\/strong><br \/>\n        <strong>:<\/strong><br \/>\n        <br \/>818-661-5000<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-7Zk007lqLLS3Z_Aibfr4FBY6xBAho99CHZEMw1LlTaD7u8EzCiala-7vb84Ht3ajErGVr7SlmudvEFKR26jf8mlclwBBeWFEooor4qzybk=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ir@mannkindcorp.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4OTU0NSMzODM2NzA1IzIwMDgxMDc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/15013286-9bde-40a5-8c07-af6cc33b691d\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WESTLAKE VILLAGE, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; MannKind Corporation\u00a0(NASDAQ:MNKD) today announced that it has achieved the final development milestone under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil. Treprostinil Technosphere (\u201cTreT\u201d) is an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension (PAH). All current clinical trials are now fully enrolled, including the BREEZE study in patients with PAH and a pivotal pharmacokinetics study in healthy subjects, both of which are being conducted by United Therapeutics, as well as a human factors study being conducted by MannKind. In addition, MannKind\u2019s stability program for TreT has reached the milestone required for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-385690","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WESTLAKE VILLAGE, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; MannKind Corporation\u00a0(NASDAQ:MNKD) today announced that it has achieved the final development milestone under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil. Treprostinil Technosphere (\u201cTreT\u201d) is an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension (PAH). All current clinical trials are now fully enrolled, including the BREEZE study in patients with PAH and a pivotal pharmacokinetics study in healthy subjects, both of which are being conducted by United Therapeutics, as well as a human factors study being conducted by MannKind. In addition, MannKind\u2019s stability program for TreT has reached the milestone required for &hellip; Continue reading &quot;MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-19T22:03:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4OTU0NSMzODM2NzA1IzIwMDgxMDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics\",\"datePublished\":\"2020-11-19T22:03:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\\\/\"},\"wordCount\":481,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4OTU0NSMzODM2NzA1IzIwMDgxMDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\\\/\",\"name\":\"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4OTU0NSMzODM2NzA1IzIwMDgxMDc=\",\"datePublished\":\"2020-11-19T22:03:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4OTU0NSMzODM2NzA1IzIwMDgxMDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4OTU0NSMzODM2NzA1IzIwMDgxMDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics - Market Newsdesk","og_description":"WESTLAKE VILLAGE, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; MannKind Corporation\u00a0(NASDAQ:MNKD) today announced that it has achieved the final development milestone under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil. Treprostinil Technosphere (\u201cTreT\u201d) is an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension (PAH). All current clinical trials are now fully enrolled, including the BREEZE study in patients with PAH and a pivotal pharmacokinetics study in healthy subjects, both of which are being conducted by United Therapeutics, as well as a human factors study being conducted by MannKind. In addition, MannKind\u2019s stability program for TreT has reached the milestone required for &hellip; Continue reading \"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-19T22:03:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4OTU0NSMzODM2NzA1IzIwMDgxMDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics","datePublished":"2020-11-19T22:03:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\/"},"wordCount":481,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4OTU0NSMzODM2NzA1IzIwMDgxMDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\/","name":"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4OTU0NSMzODM2NzA1IzIwMDgxMDc=","datePublished":"2020-11-19T22:03:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4OTU0NSMzODM2NzA1IzIwMDgxMDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4OTU0NSMzODM2NzA1IzIwMDgxMDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/385690","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=385690"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/385690\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=385690"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=385690"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=385690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}